Treatment options for osteoporosis are limited for older individuals with chronic kidney disease. A secondary analysis of the FREEDOM trial sheds light on the efficacy and safety of denosumab in patients with impaired kidney function, but underlines that challenges remain in the treatment of osteoporosis in patients with severe chronic kidney disease.
- Jorge B. Cannata-Andía
- Carlos Gómez-Alonso